Do I Qualify for Wegovy, Zepbound or Another GLP-1?

“Do I qualify?” is the first question almost everyone asks, and it turns out to have three different answers depending on who is asking.

The FDA label says who a drug was approved for. Your doctor decides whether it is appropriate for you. Your insurance plan decides whether it will pay. Those three gates do not line up, and people get stuck because they only checked one of them.

This guide walks through all three, drug by drug, using the labels themselves.

What does “qualify” actually mean?

There is no application, no board, and no official qualification. When people ask if they qualify, they usually mean one of these:

• Am I in the group the FDA approved this drug for? That is the labeled indication, and it is written on the prescribing information [1][2].
• Will a clinician agree to prescribe it? That is a medical judgment, and it includes checking for reasons you should not take it.
• Will my plan pay? That is a separate coverage decision with its own rules [3].

You can clear the first two and still fail the third. That is the single most common frustration in this whole category.

What BMI do you need for Wegovy or Zepbound?

Here is a detail that surprises people: the current labels for Wegovy and Zepbound no longer print BMI numbers in the indications section.

Wegovy injection is indicated, alongside a reduced-calorie diet and more physical activity, “to reduce excess body weight and maintain weight reduction long term” in adults with obesity, and in adults with overweight who have at least one weight-related comorbid condition [1]. Zepbound uses nearly identical wording [2]. Foundayo, the once-daily orforglipron tablet approved by the FDA on April 1, 2026, uses the same wording again [4][14].

So where does “BMI 30, or 27 with a condition” come from? Two places.

First, the trials. Zepbound’s pivotal studies enrolled adults “with obesity (BMI ≥30 kg/m²), or with overweight (BMI 27 to <30 kg/m²) and at least one weight-related comorbid condition, such as dyslipidemia, hypertension, obstructive sleep apnea, or CV disease” [2]. The diabetes study enrolled adults with a BMI of 27 or above plus type 2 diabetes [2].

Second, the guidelines. The American Diabetes Association’s 2026 Standards of Care describes FDA-approved obesity medicines as approved for people with “BMI ≥30 kg/m² or ≥27 kg/m² with one or more obesity-associated comorbid conditions” [5].

There is now a third place, and it is the most concrete of the three. The Medicare GLP-1 Bridge, the CMS demonstration that began July 1, 2026, publishes explicit numeric eligibility criteria: a BMI of 35 or higher; or a BMI of 30 or higher with diastolic heart failure, uncontrolled hypertension, or chronic kidney disease at stage 3a or higher; or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease [14]. That is a federal program printing the numbers the labels no longer print.

The ADA also gives the standard BMI bands [5]:

Category	BMI
Overweight	25 to 29.9
Obesity class 1	30 to 34.9
Obesity class 2	35 to 39.9
Obesity class 3	40 and above

You can calculate yours with the free NHLBI calculator, which takes height and weight and returns a number and a category [6].

What counts as a weight-related condition?

This is where the vague label wording causes real problems, because no label publishes a complete list.

The conditions actually named in the Zepbound trial criteria are [2]:

• Abnormal cholesterol or triglycerides (dyslipidemia)
• High blood pressure (hypertension)
• Obstructive sleep apnea
• Cardiovascular disease

ADA adds type 2 diabetes, hypertension and dyslipidemia as examples when describing the 27-plus-comorbidity group [5].

In everyday practice, clinicians also commonly count prediabetes, fatty liver disease, osteoarthritis and polycystic ovary syndrome. Those are widely accepted but they are not in the Zepbound trial list, so whether a given plan accepts them varies. If you are near the line, this is worth asking about before the prescription is written rather than after it is denied.

Which GLP-1 is labeled for weight, and which is labeled for diabetes?

This is the second big source of confusion, because the same molecule is sold under different names for different purposes.

Approved for weight management:

• Wegovy injection (semaglutide), weekly. Adults with obesity; adults with overweight plus a weight-related condition; and adolescents 12 and older with obesity. It also carries separate approvals for cardiovascular risk reduction and for noncirrhotic MASH liver disease with F2-F3 fibrosis [1].
• Wegovy tablets (semaglutide), daily. Adults only, for weight and for cardiovascular risk reduction. No pediatric or MASH indication [1].
• Zepbound (tirzepatide), weekly. Adults, for weight and separately for moderate to severe obstructive sleep apnea in adults with obesity [2].
• Foundayo (orforglipron), daily tablet. Adults only, for weight [4].
• Saxenda (liraglutide), daily injection. Labeled for “adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity,” and separately for adults with overweight plus at least one weight-related comorbid condition [7].

Approved for type 2 diabetes only:

• Ozempic (semaglutide), weekly injection. Adults with type 2 diabetes, plus specific heart and kidney uses in that group [8].
• Rybelsus and Ozempic tablets (oral semaglutide), daily. Adults with type 2 diabetes [9].
• Mounjaro (tirzepatide), weekly. Adults and children 10 and older with type 2 diabetes [10].
• Trulicity (dulaglutide), weekly. Adults and children 10 and older with type 2 diabetes [11].

Notice the pattern. Ozempic and Wegovy are the same drug. Mounjaro and Zepbound are the same drug. The brands differ because the approved uses and the dose ladders differ.

Do I qualify for Ozempic if I just want to lose weight?

Not under the label. Ozempic is approved only for adults with type 2 diabetes [8]. Using it purely for weight loss is what the FDA calls an unapproved or off-label use.

The FDA’s position is that “once the FDA approves a drug, healthcare providers generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate for their patient” [12]. So it is legal. But the FDA also cautions that in that situation “FDA has not determined that the drug is safe and effective for the unapproved use,” and suggests you ask about approved alternatives, the evidence behind the off-label use, and whether insurance will cover it [12].

In practice, insurers deny off-label GLP-1 requests routinely, which is why so many people who were prescribed Ozempic for weight ended up paying cash or switching to Wegovy.

Can a teenager qualify?

Sometimes, and the rules are specific.

Wegovy injection is labeled for adolescents aged 12 and older with obesity. The supporting trial enrolled 201 pubertal patients aged 12 and up whose BMI was at or above the 95th percentile standardized for age and sex, with a mean age of 15 and a mean starting BMI of 37 [1]. Note that for children and teens, obesity is defined by percentile for age and sex, not by a single BMI number.

Saxenda’s indication reads “adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity,” so the 60 kg floor is part of the labeled population, not a separate rule. Its label also notes safety and effectiveness have not been established in pediatric patients with type 2 diabetes [7].

Zepbound’s label states directly that safety and effectiveness “have not been established in pediatric patients” [2]. Foundayo is labeled for adults only [4].

For type 2 diabetes rather than weight, Mounjaro and Trulicity both go down to age 10 [10][11].

What would disqualify me?

Every drug in this class carries the same core contraindications. You cannot take them if you have [1][2][7][10]:

• A personal or family history of medullary thyroid carcinoma, a rare thyroid cancer
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• A known serious allergic reaction to the drug or its ingredients

The labels also say these drugs are not recommended in people with severe gastroparesis, a condition where the stomach empties too slowly [1][2].

There are also situations that change the conversation rather than ending it. The weight-management labels say these drugs may cause fetal harm and should be stopped when pregnancy is recognized, and Wegovy’s label advises stopping at least two months before a planned pregnancy because semaglutide stays in the body a long time [1]. None of this is something to work out alone. It is exactly what a first appointment is for.

Why does my insurance use different rules than the FDA?

Because it can. Coverage is a contract term, not a medical standard.

Business Group on Health’s 2026 GLP-1 survey, fielded in February and March 2026 among 105 large member employers, found that 67 percent covered GLP-1s for weight management at all, and that employers who do cover them lean on utilization management: “validating clinical eligibility via objective biometric data, requiring participation in a weight management program to receive coverage, limiting prescribing to specific providers and excluding certain medications from the formulary” [3]. In practice that means a plan can require a BMI of 35 instead of 30, or demand a documented history of supervised weight-loss attempts, or require you to try one drug before another.

Coverage is also contracting rather than expanding. In the same survey, only 72 percent of employers currently covering GLP-1s for weight management said they were likely to continue in 2027, while 10 percent said they likely would not [3].

Some plans go further and exclude anti-obesity medication as a whole benefit category. When that happens, the drug can be on the formulary and still not be covered for you, because the exclusion sits above the formulary.

This is also why the sleep apnea indication matters so much. Zepbound’s approval for moderate to severe obstructive sleep apnea in adults with obesity is a separate indication [2], and some plans that will not pay for weight loss will pay for sleep apnea treatment.

Is BMI even the right test?

The guideline bodies themselves say it is imperfect.

ADA’s 2026 Standards of Care states that BMI “is not a perfect measure of adipose tissue mass,” does not measure fat distribution or function, and “is especially prone to misclassification in individuals who are very muscular (athletes) or in those with low muscle mass” [5]. It recommends confirming excess body fat with at least one additional measure such as waist circumference, waist-to-hip ratio or waist-to-height ratio, especially in the BMI 25 to 34.9 range [5].

A Lancet Diabetes & Endocrinology Commission published in January 2025, developed by 58 experts and endorsed by 76 organizations, went further. It proposed distinguishing “clinical obesity,” where excess fat is already causing documented organ dysfunction or limiting daily activities, from “preclinical obesity,” where organ function is preserved. It recommended BMI be used “only as a surrogate measure of health risk at a population level… rather than as an individual measure of health,” and noted that above a BMI of 40, excess adiposity can simply be assumed [13].

That framework argues clinical obesity should not require a second disease to justify treatment or coverage, which is the opposite of how the “BMI 27 plus a comorbidity” insurance model works [13]. It has not changed FDA labeling or most US payer policy as of September 2026, but it is shaping how specialists talk about eligibility.

So what should I actually do next?

A realistic sequence:

1. Calculate your BMI with a free tool so you know roughly where you sit [6].
2. List your weight-related conditions, including anything diagnosed but not currently treated. Sleep apnea, blood pressure and cholesterol are the ones people most often forget to mention.
3. Check your plan before the appointment. Find the formulary, search for Wegovy, Zepbound and Foundayo by brand, and call member services to ask whether anti-obesity medication is a covered category at all. If you are on Medicare Part D, the GLP-1 Bridge eligibility screener at Medicare.gov publishes its criteria directly [14].
4. Bring all of it to a clinician, along with your full medication list and your family history of thyroid cancer.

Everything above summarizes FDA-approved prescribing information and the accompanying Instructions for Use, plus published guidelines and federal coverage rules. It does not tell you whether a GLP-1 is right for you, what dose to take, or whether to change anything you are currently doing. Follow your own prescription, the Instructions for Use that came with your product, and the provider who knows your history.

Sources

1. WEGOVY (semaglutide) injection and tablets — US Prescribing Information, DailyMed
2. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Eli Lilly
3. Business Group on Health, 2026 GLP-1 survey
4. FOUNDAYO (orforglipron) tablets — US Prescribing Information, DailyMed
5. American Diabetes Association, Section 8: Obesity and Weight Management, Standards of Care in Diabetes–2026
6. NHLBI Calculate Your BMI
7. SAXENDA (liraglutide) injection — US Prescribing Information, DailyMed
8. OZEMPIC (semaglutide) injection — US Prescribing Information, DailyMed
9. RYBELSUS and OZEMPIC (oral semaglutide) tablets — US Prescribing Information, DailyMed
10. MOUNJARO (tirzepatide) injection — US Prescribing Information, DailyMed
11. TRULICITY (dulaglutide) injection — US Prescribing Information, DailyMed
12. FDA, Understanding Unapproved Use of Approved Drugs “Off Label”
13. Rubino F, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol, 2025
14. Medicare.gov, Weight loss drugs — Medicare GLP-1 Bridge eligibility
15. FDA, FDA Approves First New Molecular Entity Under National Priority Voucher Program (Foundayo, April 1, 2026)